Northern Trust
ACRS icon

Northern Trust’s Aclaris Therapeutics ACRS Stock Holding History

Northern Trust’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.73M Buy
728,225
+63,967
+10% +$216K ﹤0.01% 2806
2025
Q4 		$2M Sell
664,258
-36,565
-5% -$92.4K ﹤0.01% 2999
2025
Q3 		$1.33M Sell
700,823
-65,432
-9% -$114K ﹤0.01% 3250
2025
Q2 		$1.09M Buy
766,255
+497,169
+185% +$673K ﹤0.01% 3336
2025
Q1 		$412K Buy
269,086
+93,911
+54% +$200K ﹤0.01% 3653
2024
Q4 		$434K Buy
175,175
+47,950
+38% +$119K ﹤0.01% 3704
2024
Q3 		$146K Sell
127,225
-393,244
-76% -$482K ﹤0.01% 3970
2024
Q2 		$573K Sell
520,469
-41,755
-7% -$49.1K ﹤0.01% 3457
2024
Q1 		$697K Sell
562,224
-97,413
-15% -$116K ﹤0.01% 3451
2023
Q4 		$693K Buy
659,637
+266
+0% +$812 ﹤0.01% 3436
2023
Q3 		$4.52M Buy
659,371
+9,444
+1% +$80.7K ﹤0.01% 2511
2023
Q2 		$6.74M Buy
649,927
+84,984
+15% +$769K ﹤0.01% 2323
2023
Q1 		$4.57M Sell
564,943
-2,526
-0.4% -$32.1K ﹤0.01% 2532
2022
Q4 		$8.94M Buy
567,469
+13,985
+3% +$225K ﹤0.01% 2081
2022
Q3 		$8.71M Buy
553,484
+29,805
+6% +$470K ﹤0.01% 2077
2022
Q2 		$7.31M Buy
523,679
+53,513
+11% +$750K ﹤0.01% 2260
2022
Q1 		$8.11M Sell
470,166
-19,630
-4% -$268K ﹤0.01% 2277
2021
Q4 		$7.12M Sell
489,796
-11,837
-2% -$179K ﹤0.01% 2477
2021
Q3 		$9.03M Buy
501,633
+45,197
+10% +$725K ﹤0.01% 2350
2021
Q2 		$8.02M Buy
456,436
+347,641
+320% +$7.9M ﹤0.01% 2526
2021
Q1 		$2.74M Buy
108,795
+18,108
+20% +$354K ﹤0.01% 3081
2020
Q4 		$586K Sell
90,687
-5,095
-5% -$21.5K ﹤0.01% 3685
2020
Q3 		$247K Sell
95,782
-2,824
-3% -$6.32K ﹤0.01% 3770
2020
Q2 		$160K Sell
98,606
-256,521
-72% -$344K ﹤0.01% 3812
2020
Q1 		$370K Buy
355,127
+11,275
+3% +$15.3K ﹤0.01% 3528
2019
Q4 		$650K Sell
343,852
-34,442
-9% -$57.1K ﹤0.01% 3504
2019
Q3 		$409K Sell
378,294
-53,168
-12% -$75.4K ﹤0.01% 3591
2019
Q2 		$945K Sell
431,462
-4,119
-0.9% -$22.5K ﹤0.01% 3376
2019
Q1 		$2.61M Sell
435,581
-9,361
-2% -$62.1K ﹤0.01% 2917
2018
Q4 		$3.29M Buy
444,942
+90,791
+26% +$936K ﹤0.01% 2758
2018
Q3 		$5.14M Buy
354,151
+59,118
+20% +$1.01M ﹤0.01% 2667
2018
Q2 		$5.89M Sell
295,033
-538
-0.2% -$9.94K ﹤0.01% 2602
2018
Q1 		$5.18M Buy
295,571
+4,048
+1% +$85.8K ﹤0.01% 2563
2017
Q4 		$7.19M Sell
291,523
-1,736
-0.6% -$42.3K ﹤0.01% 2390
2017
Q3 		$7.57M Buy
293,259
+37,521
+15% +$1.01M ﹤0.01% 2371
2017
Q2 		$6.94M Buy
255,738
+87,250
+52% +$2.37M ﹤0.01% 2414
2017
Q1 		$5.02M Buy
168,488
+16,767
+11% +$483K ﹤0.01% 2548
2016
Q4 		$4.12M Buy
151,721
+42,583
+39% +$1.09M ﹤0.01% 2667
2016
Q3 		$2.79M Buy
109,138
+33,430
+44% +$709K ﹤0.01% 2881
2016
Q2 		$1.4M Buy
75,708
+18,357
+32% +$364K ﹤0.01% 3219
2016
Q1 		$1.09M Buy
57,351
+209
+0.4% +$3.99K ﹤0.01% 3227
2015
Q4 		$1.54M Buy
+57,142
New +$1.11M ﹤0.01% 3173

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Northern Trust's ACRS Position: Q1 2026 in Review

Northern Trust increased its Aclaris Therapeutics (ACRS) stake by 9.6% in Q1 2026, buying an estimated $216K and bringing the position to 728,225 shares worth $2.73M. The position accounts for ﹤0.01% of the portfolio, ranked #2806.

Northern Trust first reported a position in ACRS in Q4 2015 and has held it in 42 quarters since. The position peaked at $9.03M in Q3 2021. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Northern Trust held 728,225 shares of Aclaris Therapeutics worth $2.73M as of Q1 2026.
  • Northern Trust bought 63,967 Aclaris Therapeutics shares in Q1 2026, an estimated $216K.
  • Aclaris Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2806 holding.
  • Northern Trust first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 42 quarters since.
  • Northern Trust's Aclaris Therapeutics position peaked at $9.03M in Q3 2021.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.